ES2360331B8 - Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas. - Google Patents

Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas. Download PDF

Info

Publication number
ES2360331B8
ES2360331B8 ES200930901A ES200930901A ES2360331B8 ES 2360331 B8 ES2360331 B8 ES 2360331B8 ES 200930901 A ES200930901 A ES 200930901A ES 200930901 A ES200930901 A ES 200930901A ES 2360331 B8 ES2360331 B8 ES 2360331B8
Authority
ES
Spain
Prior art keywords
corm
crocus sativus
saponins
vaccine formulations
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES200930901A
Other languages
English (en)
Other versions
ES2360331B1 (es
ES2360331A1 (es
Inventor
Angela Rubio Moraga
Jose Antonio Fernandez Perez
Nathaly Castro Diaz
Pedro Romero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Castilla La Mancha
Original Assignee
Universidad de Castilla La Mancha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Castilla La Mancha filed Critical Universidad de Castilla La Mancha
Priority to ES200930901A priority Critical patent/ES2360331B8/es
Priority to PCT/ES2010/070626 priority patent/WO2011051520A1/es
Publication of ES2360331A1 publication Critical patent/ES2360331A1/es
Publication of ES2360331B1 publication Critical patent/ES2360331B1/es
Application granted granted Critical
Publication of ES2360331B8 publication Critical patent/ES2360331B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Saponinas triterpénicas procedentes del cormo de Crocus Sativus como adyuvante en formulaciones de vacunas proteicas.#La presente invención se refiere a unas nuevas saponinas triterpénicas procedentes del cormo del azafrán (Crocus sativus L.), a una composición que las comprende, a su uso como sustancias adyuvantes en vacunas proteicas así como en la elaboración de medicamentos, preferiblemente para el tratamiento del cáncer y más preferiblemente para el tratamiento del carcinoma cervical, y a un método de obtención de las mismas. El empleo de estas saponinas triterpénicas como adyuvantes en vacunas deriva en una respuesta inmune incrementada, funcional y duradera frente al antígeno, superior a la de otras sustancias con capacidad inmunopotenciadora tales como las sales de aluminio, IFA (adyuvante incompleto de Freund), CpG (secuencias cortas de DNA bacteriano de citosina, fosfato y guanina) e incluso otras saponinas como QuilA, sin presentar los efectos adversos que habitualmente se observan bajo la administración de estos otros adyuvantes.
ES200930901A 2009-10-26 2009-10-26 Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas. Active ES2360331B8 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200930901A ES2360331B8 (es) 2009-10-26 2009-10-26 Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas.
PCT/ES2010/070626 WO2011051520A1 (es) 2009-10-26 2010-09-28 Saponinas triterpenicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930901A ES2360331B8 (es) 2009-10-26 2009-10-26 Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas.

Publications (3)

Publication Number Publication Date
ES2360331A1 ES2360331A1 (es) 2011-06-03
ES2360331B1 ES2360331B1 (es) 2012-07-04
ES2360331B8 true ES2360331B8 (es) 2013-01-29

Family

ID=43921393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200930901A Active ES2360331B8 (es) 2009-10-26 2009-10-26 Saponinas triterpénicas procedentes del cormo de crocus sativus como adyuvante en formulaciones de vacunas proteicas.

Country Status (2)

Country Link
ES (1) ES2360331B8 (es)
WO (1) WO2011051520A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3033106A1 (en) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunoadjuvant compositions and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009075A2 (en) * 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants

Also Published As

Publication number Publication date
ES2360331B1 (es) 2012-07-04
WO2011051520A1 (es) 2011-05-05
ES2360331A1 (es) 2011-06-03

Similar Documents

Publication Publication Date Title
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
Haq et al. Immunosenescence: influenza vaccination and the elderly
Reed et al. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
NZ717594A (en) Oil-based adjuvants
Alexyuk et al. Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins
BRPI0920791B8 (pt) Uso de peptídeo na preparação de medicamento para tratar câncer e kit
EA202091233A2 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
TW200722101A (en) Novel composition
EP3456339A3 (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc
Liang et al. Comparison of 3 kinds of Toll-like receptor ligands for inactivated avian H5N1 influenza virus intranasal immunization in chicken
CL2019000704A1 (es) Vectores de adenovirus canino.
Del Giudice et al. Vaccines for the elderly
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112017018017A2 (pt) composição de vacina compreendendo uma proteína imunogênica e adjuvantes de combinação para uso na promoção de respostas de células t específicas de antigenos
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
Cheng et al. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge
Xie et al. A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum
WO2008054535A3 (en) Novel influenza m2 vaccines
JP2018526390A5 (es)
JP2016106117A5 (es)
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
Vemula et al. Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2360331

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120704